Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Can Protagonist Therapeutics (PTGX) Climb 323% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 323.4% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 337%
by Zacks Equity Research
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 337.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 322% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 322.3% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%
by Zacks Equity Research
The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 15.15% and 62.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Soars 5.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 35.82% and 33.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Soars 5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 14th
by Zacks Equity Research
ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -11.29% and -59.55%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Company News for Jun 14, 2021
by Zacks Equity Research
Companies In The News Are: VRTX, RCL, AAL, PTGX
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -2.13% and 67.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.